Cathy Chognot

803 total citations
12 papers, 556 citations indexed

About

Cathy Chognot is a scholar working on Pathology and Forensic Medicine, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Cathy Chognot has authored 12 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 4 papers in Epidemiology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Cathy Chognot's work include Multiple Sclerosis Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). Cathy Chognot is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). Cathy Chognot collaborates with scholars based in Switzerland, United States and Germany. Cathy Chognot's co-authors include Michael Rabbia, Sunder Mudaliar, A. Michael Lincoff, Robert R. Henry, Matthias Herz, Amit Bar‐Or, Daniela Stokmaier, Kevin Winthrop, Marianna Manfrini and Jonathan Calkwood and has published in prestigious journals such as The Lancet, Neurology and Therapeutic Advances in Neurological Disorders.

In The Last Decade

Cathy Chognot

12 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cathy Chognot Switzerland 6 304 161 155 136 118 12 556
Heleia Roca-Ho Spain 12 41 0.1× 87 0.5× 219 1.4× 98 0.7× 158 1.3× 21 648
Elisabetta Macerola Italy 16 89 0.3× 55 0.3× 100 0.6× 49 0.4× 119 1.0× 49 745
Leandro Jimenez Brazil 6 33 0.1× 80 0.5× 208 1.3× 78 0.6× 117 1.0× 7 526
Hanna J. Lee United States 7 61 0.2× 25 0.2× 48 0.3× 87 0.6× 89 0.8× 9 485
Julian Friebel Germany 14 82 0.3× 21 0.1× 44 0.3× 98 0.7× 204 1.7× 27 537
László Rejtő Hungary 9 60 0.2× 21 0.1× 38 0.2× 59 0.4× 108 0.9× 33 376
Paola Cruz‐Tapias Colombia 12 80 0.3× 17 0.1× 28 0.2× 176 1.3× 85 0.7× 17 544
Arzu Didem Yalçın Türkiye 15 73 0.2× 22 0.1× 40 0.3× 152 1.1× 97 0.8× 68 585
Fred V. Plapp United States 13 86 0.3× 41 0.3× 18 0.1× 99 0.7× 66 0.6× 30 594
Leonie Frauenfeld Germany 10 72 0.2× 58 0.4× 99 0.6× 53 0.4× 128 1.1× 26 517

Countries citing papers authored by Cathy Chognot

Since Specialization
Citations

This map shows the geographic impact of Cathy Chognot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathy Chognot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathy Chognot more than expected).

Fields of papers citing papers by Cathy Chognot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathy Chognot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathy Chognot. The network helps show where Cathy Chognot may publish in the future.

Co-authorship network of co-authors of Cathy Chognot

This figure shows the co-authorship network connecting the top 25 collaborators of Cathy Chognot. A scholar is included among the top collaborators of Cathy Chognot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathy Chognot. Cathy Chognot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Cerqueira, João, Achim Berthele, Bruce Cree, et al.. (2025). Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS. Neurology. 104(4). e210142–e210142. 7 indexed citations
2.
Derfuß, Tobias, Robert A Bermel, Chien‐Ju Lin, et al.. (2024). Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. Therapeutic Advances in Neurological Disorders. 17. 4233558824–4233558824. 5 indexed citations
3.
Hauser, Stephen L., Ludwig Kappos, Massimo Filippi, et al.. (2024). 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005). Neurology. 102(7_supplement_1). 4 indexed citations
4.
Wilke, Thomas, et al.. (2023). Comparing the risk of serious infections in patients with and without MS: A German claims data analysis. Multiple Sclerosis and Related Disorders. 72. 104583–104583. 1 indexed citations
5.
Kappos, Ludwig, et al.. (2023). Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 80. 105308–105308. 2 indexed citations
6.
Cerqueira, João, Achim Berthele, Bruce Cree, et al.. (2023). Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002). Neurology. 100(17_supplement_2). 1 indexed citations
7.
Wilke, Thomas, et al.. (2022). Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study. Multiple Sclerosis and Related Disorders. 68. 104245–104245. 8 indexed citations
8.
Hauser, Stephen L., Ludwig Kappos, Xavier Montalbán, et al.. (2021). Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. Neurology. 97(16). e1546–e1559. 115 indexed citations
9.
Bar‐Or, Amit, Jonathan Calkwood, Cathy Chognot, et al.. (2020). Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology. 95(14). e1999–e2008. 230 indexed citations
10.
Stokmaier, Daniela, et al.. (2018). Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002). Neurology. 90(15_supplement). 19 indexed citations
11.
Wolinsky, Jerry S., Ludwig Kappos, Xavier Montalbán, et al.. (2018). Routine Laboratory Measures in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis (P5.425). Neurology. 90(15_supplement). 2 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heleia Roca-Ho Breakdown of academic impact, for papers by Elisabetta Macerola Breakdown of academic impact, for papers by Leandro Jimenez Breakdown of academic impact, for papers by Hanna J. Lee Breakdown of academic impact, for papers by Julian Friebel Breakdown of academic impact, for papers by László Rejtő Breakdown of academic impact, for papers by Paola Cruz‐Tapias Breakdown of academic impact, for papers by Arzu Didem Yalçın Breakdown of academic impact, for papers by Fred V. Plapp Breakdown of academic impact, for papers by Leonie Frauenfeld
Rankless by CCL
2026